Is ALTH a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

215 people get ALTH articles and Market Currents by email alert.

Get email alerts on ALTH »

HEADLINES:

2 Roaring Sectors: Are They Still A Buy?
BubbleBustInvesting • Mon, Sep 10, 2012 • 2 Comments
Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics

Business Wire (Sep 4, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012

Business Wire (Aug 28, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Aug 17, 2012)
3 Biotech Companies Showing Promise In Radiotherapy Treatment
Cris Frangold • Fri, Aug 17, 2012
Cash Rich, Fast Growing Biotech With Further Upside Ahead
Bret Jensen • Sun, Aug 5, 2012 • 11 Comments
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Aug 3, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Jul 20, 2012)
Double Digit Premiums In U.S. Merger Arbitrage Plays: Part 2
Rajiv Tarigopula • Wed, Jul 18, 2012 • 4 Comments
Spectrum Pharmaceuticals: Bears Beware, Fusilev Strength Points To Strong Second Quarter
Smith On Stocks • Sun, Jul 15, 2012 • 23 Comments
Keryx: A Lot Can Go Wrong At $2
Vatalyst • Fri, Jul 13, 2012 • 17 Comments
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Jul 6, 2012)
June's Merger Arbitrage Option Plays
Value Research • Tue, Jun 26, 2012 • 6 Comments
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Jun 21, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Jun 7, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (May 24, 2012)
Bio-Pharma Catalyst Trades And ASCO Movers: Making The Grade
Scott Matusow • Tue, May 15, 2012 • 21 Comments
Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics

Business Wire (May 10, 2012)
Today's Bio-Pharma Catalyst Trades And ASCO Movers
Scott Matusow • Tue, May 8, 2012 • 15 Comments
Merger Arbitrage Mondays: May 7, 2012
Asif Suria • Mon, May 7, 2012 • 2 Comments

To learn more about Seeking Alpha Pro, click here.

Allos Therapeutics Evenly Poised, But Competition Lurks
Zacks Investment Research • Wed, Mar 30, 2011
Allos Therapeutics: Comeback Stock of the Year?
StreetAuthority • Tue, Mar 29, 2011 • 1 Comment
Betting Big on Allos' New Cancer Drug
optionMONSTER • Fri, Apr 2, 2010 • 1 Comment
A Vote of Confidence for Allos
optionMONSTER • Wed, Jan 6, 2010
Market Jitters Affect Allos
EP Vantage • Sun, Sep 6, 2009 • 2 Comments
Allos Therapeutics: Prospects for FDA Approval of Folotyn Are Healthy
M. E. Garza • Fri, Sep 4, 2009 • 1 Comment
Allos Therapeutics: Smallcap Biotech with FDA Catalyst
Mike Havrilla • Mon, Apr 27, 2009 • 1 Comment
Allos Therapeutics Looks Promising Ahead of Crucial 6 Months
EP Vantage • Tue, Jul 15, 2008

2 Roaring Sectors: Are They Still A Buy?
BubbleBustInvesting • Mon, Sep 10, 2012 • 2 Comments
3 Biotech Companies Showing Promise In Radiotherapy Treatment
Cris Frangold • Fri, Aug 17, 2012
Cash Rich, Fast Growing Biotech With Further Upside Ahead
Bret Jensen • Sun, Aug 5, 2012 • 11 Comments
Double Digit Premiums In U.S. Merger Arbitrage Plays: Part 2
Rajiv Tarigopula • Wed, Jul 18, 2012 • 4 Comments
Spectrum Pharmaceuticals: Bears Beware, Fusilev Strength Points To Strong Second Quarter
Smith On Stocks • Sun, Jul 15, 2012 • 23 Comments
Keryx: A Lot Can Go Wrong At $2
Vatalyst • Fri, Jul 13, 2012 • 17 Comments
June's Merger Arbitrage Option Plays
Value Research • Tue, Jun 26, 2012 • 6 Comments
Bio-Pharma Catalyst Trades And ASCO Movers: Making The Grade
Scott Matusow • Tue, May 15, 2012 • 21 Comments
Today's Bio-Pharma Catalyst Trades And ASCO Movers
Scott Matusow • Tue, May 8, 2012 • 15 Comments
Merger Arbitrage Mondays: May 7, 2012
Asif Suria • Mon, May 7, 2012 • 2 Comments
Spectrum: A Deeply Undervalued $10 Stock To Buy Now
ValueMax • Thu, May 3, 2012 • 14 Comments
Spectrum's Undervalued Stock Could Rise If Folotyn Succeeds
Mel Daris • Fri, Apr 27, 2012
Spectrum Could Sink In Wake Of Trial Failures
Investment Underground • Sun, Apr 22, 2012 • 17 Comments
Valeant Ready To Spring Higher On New Atlantis Pharma Deal
Investment Underground • Fri, Apr 20, 2012 • 1 Comment
Keryx Will Tank Without The Success Of Zerenex
Vatalyst • Fri, Apr 20, 2012 • 9 Comments
Spectrum Could Sink On Aqaziquone Failure
IncomeHunter • Wed, Apr 18, 2012 • 18 Comments
Second Physician Survey Supports Prescription Data: Expecting 1Q Fusilev Growth
LifeSci Advisors • Tue, Apr 17, 2012 • 27 Comments
A Reevaluation Of Spectrum Pharmaceuticals
Peter Li • Wed, Apr 11, 2012 • 7 Comments
Time To Take Another Look At The Biotechnology Sector
BubbleBustInvesting • Mon, Apr 9, 2012 • 6 Comments
Upcoming ASCO Meeting Could Move These Stocks
Brian Nichols • Wed, Apr 4, 2012 • 6 Comments

Allos Therapeutics CEO Discusses Q3 2010 Results - Earnings Call Transcript
Sun, Nov 7, 2010 • 2 Comments
Allos Therapeutics, Inc. Q2 2010 Earnings Call Transcript
Wed, Jul 28, 2010
Allos Therapeutics, Inc. Q1 2010 Earnings Call Transcript
Wed, May 5, 2010
Allos Therapeutics, Inc., Q3 2009 Earnings Call Transcript
Tue, Nov 3, 2009
Allos Therapeutics, Inc. Q4 2008 Earnings Call Transcript
Thu, Mar 19, 2009
Allos Therapeutics Inc. Q3 2008 Earnings Call Transcript
Thu, Nov 6, 2008
Allos Therapeutics, Inc. Q2 2008 Earnings Call Transcript
Mon, Sep 8, 2008
Allos Therapeutics Inc. Q1 2008 Earnings Call Transcript
Mon, May 26, 2008
Allos Therapeutics, Inc Q4 2007 Earnings Call Transcript
Thu, Apr 17, 2008
Allos Therapeutics Q3 2007 Earnings Call Transcript
Mon, Nov 5, 2007

Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics

Business Wire (Sep 4, 2012)
WellPoint, Iron Mountain Incorporated Among Stocks Up on High Volume Wednesday

at Fox Business (Aug 29, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce That FTC Clears Transaction; Tender Offer for Shares of Allos Common Stock To Expire at 5pm Eastern Time on September 4, 2012

Business Wire (Aug 28, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Aug 17, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Aug 3, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Jul 20, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Jul 6, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Jun 21, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (Jun 7, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics

Business Wire (May 24, 2012)
Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics

Business Wire (May 10, 2012)
Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe

Business Wire (Apr 20, 2012)
Stocks to Watch: PLCM, BBBY, RT & More

at CNBC.com (Apr 5, 2012)
Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN

Business Wire (Jan 20, 2012)
Allos Therapeutics Reports 2011 Financial Highlights and Key Business Priorities

Business Wire (Jan 10, 2012)
Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference

Business Wire (Dec 21, 2011)
Small Caps Confirm Bullish Trend For Stocks

at CNBC.com (Oct 27, 2011)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Jul 20, 2011)
Earnings Watch: Updates, advisories and surprises

at MarketWatch.com (May 11, 2011)
Biotech Stocks: Drug stocks slide, but Teva shines

at MarketWatch.com (May 11, 2011)

ALTH vs. ETF Alternatives

Company Description

We incorporated in the Commonwealth of Virginia on September 1, 1992 as HemoTech Sciences, Inc. and filed amended Articles of Incorporation to change our name to Allos Therapeutics, Inc. on October 19, 1994. We reincorporated in Delaware on October 28, 1996. We completed our initial public... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, August 29, 2012, 11:52 AM Spectrum Pharmaceuticals (SPPI +4.6%) says the FTC has cleared its acquisition of Allos Therapeutics (ALTH +1.1%). SPPI has been looking to boost its hematology franchise, and has been chasing ALTH over most of the summer in pursuit of its lymphoma drug Folotyn. The tender offer for Allos shares is slated to expire at 5pm EST on September 4, 2012. 3 Comments [Healthcare, M&A, On the Move]
Tuesday, July 17, 2012, 1:02 PM Allos (ALTH) storms 19.6% higher after Spectrum (SPPI -0.9%) provides reassurances that its $206M+ acquisition of Allos is progressing well and that the company was "very happy with everything." Allos' shares plunged 20% yesterday on rumors that the deal had fallen through. 1 Comment [On the Move, Healthcare]
Thursday, April 5, 2012, 8:52 AM Allos Therapeutics (ALTH) roars to a 27.9% gain premarket up to $1.85 a share after Spectrum Pharmaceuticals (SPPI) agrees to buy the company. The trading price falls in the range between the offering price of $1.82/share and the $1.93-a-share value of the deal with kickers. Shares of SPPI -9.9% premarket, reeling from a negative results from a trial on apaziquone. Comment! [On the Move, Healthcare, M&A]
Thursday, April 5, 2012, 8:50 AM Premarket gainers: ALTH +28%. LLEN +14%. WOLF +11%. BBBY +5%. ZLCS +4%. GFI +3%. TLK +3%.
Losers: PLCM -19%. CKEC -10%. SPPI -10%. HOV -5%. ALU -5%. VE -4%. ING -3%. STD -3%. 1 Comment
Thursday, April 5, 2012, 7:16 AM Spectrum Pharmaceuticals (SPPI) buys Allos Therapeutics (ALTH) for $1.82 a share in a deal that also includes a $0.11/share contingency if certain European regulatory approvals and milestones for Folotyn are hit. The company expects the acquisition to be accretive in Q4. Comment! [M&A, Healthcare]
Tuesday, March 6, 2012, 4:15 PM Allos Therapeutics (ALTH): Q4 EPS of -$0.01 beats by $0.08. Revenue of $15.4M (+44.4% Y/Y) in-line. Shares -2.9% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Tuesday, January 31, 2012, 8:20 AM Shares of Allos Therapeutics (ALTH) move up 8.1% premarket on chatter that the firm could be a beneficiary of the decision by Cell Therapeutics (CTIC) to withdraw its NDA with the FDA. Comment! [Healthcare, On the Move]
Monday, January 23, 2012, 3:48 PM Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%. Comment! [Healthcare, On the Move]
Monday, January 23, 2012, 9:53 AM Shares of AMAG Pharmaceuticals (AMG -4.4%) move lower after the firm takes on a downgrade from JPMorgan to Underweight. The ratings move on AMAG is part of a larger sector call that includes VPHM, ACOR, AMGN, and ALTH all getting slashed on valuation. Comment! [On the Move, Healthcare]
Friday, January 20, 2012, 9:15 AM Premarket gainers: INSM +24%. ASIA +16%. SWKS +6%. URRE +6%. MPC +5%. BCS +4%. CTIC +4%. RBS +3%. IBM +3%. SAVE +3%. MSFT +3%.
Losers: ALTH -20%. GOOG -8%. AONE -7%. SQNM -6%. HTGC -6%. COF -6%. PH -5%. ZIOP -5%. MMLP -5%. BWP -4%. CX -4%. CUK -4%. ARCC -4%. CCL -3%. NVS -3%. MT -3%. Comment! [On the Move]
Friday, January 20, 2012, 8:42 AM Allos Therapeutics (ALTH) -19.3% premarket after receiving a negative opinion from European regulators on its Folotyn treatment for patients with peripheral T-cell lymphoma. The company says it plans to submit a request for re-examination of the opinion within two weeks. Comment! [Healthcare, On the Move]
Friday, October 21, 2011, 9:59 AM Allos Therapeutics (ALTH -6.2%) and AMAG Pharmaceuticals (AMAG +4.5%) terminate their merger agreement after AMAG shareholders fail to approve the issuance of shares of common stock to ALTH stockholders. 1 Comment [Healthcare, M&A]
Monday, October 10, 2011, 2:44 PM Allos Therapeutics (ALTH -18%) takes a hit after it says an anonymous bidder has withdrawn a takeover offer of $2.20 a share. The company says it will continue working toward with AMAG Pharmaceuticals (AMAG +2.3%). 1 Comment [Healthcare, On the Move]
Wednesday, September 21, 2011, 9:33 AM Allos Therapeutics (ALTH) is up 11%, and AMAG Pharmaceuticals (AMAG) up 2%, after Allos discloses it's received a $2.20/share offer to acquire the company, though it warns its board has not recommended the proposal. AMAG's planned buyout of Allos has been threatened by shareholder opposition following MSMB Capital's offer for AMAG. Comment! [Healthcare, On the Move, M&A]
Wednesday, September 21, 2011, 9:15 AM Premarket gainers: OREX +66%. ALTH +15%. ARNA +9%. ORCL +5%. ADBE +5%. HLS +5%. CS +4%. MCP +4%. ALU +3%. YRCW +3%.
Losers: WLT -13%. ANR -10%. PCX -5%. ACI -5%. NUVA -4%. BTU -4%. -3%. TCK -3%. Comment! [On the Move]
Wednesday, September 7, 2011, 8:54 AM The proposed $686M merger between Amag Pharmaceuticals (AMAG) and Allos Therapeutics (ALTH) could be scuttled after two large shareholders of AMAG threaten to vote against the transaction. Reports say the investors are evaluating if a management shakeup or supporting a tender offer from MSMB Capital might be better options. AMAG +8.1% premarket. Comment! [On the Move, Healthcare, M&A]

Joe Springer
Sell Spectrum! http://seekingalpha.com/a/hmw5 $SPPI $OMPI $ALTH $BMY $BIIB $UHS $WCG $CYH $TARO $PDLI $EXEL #biotech #pharma #drugs #stocks
8/23/12
Reply (5)

• !Report Abuse
View all 5 replies
phemale60: not that sophisticated - just trade. I do alright tho for a newbie. I'll learn on my next vaca - sit and read. Then I'll know! ;-/
8/23/12
• !Report Abuse
Joe Springer: : )
8/23/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
Buy Spectrum! http://seekingalpha.com/a/hmvv $SPPI $OMPI $ALTH $BMY $BIIB $UHS $WCG $CYH $TARO $PDLI $EXEL #biotech #pharma #drugs #stocks
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch: AMRN, SGYP, SPPI, ALTH, NBS, ACTC, LPTN, PFE, FB, IMSC - http://bit.ly/RujKu6
8/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/zSDYcD Earning after hours: ALTH, ASTI, SRPT, BRKS, HTWR, MDR, MCP, NABI, JWN, OPTR, NUAN, WX, TWER, STEM, LOV, PHMD
5/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
New Post: Merger Arbitrage Mondays http://bit.ly/st1w3P $DDIC $ALTH
4/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

John Rayhall
Wow ALTH bought at $1.85! I remember when it was at $8 and analysts had a $15+ target on it. Not sure it's a good move for SPPI.
4/5/12
Reply (2)

• !Report Abuse
View all 2 replies
FortSumter: I have SPPI. Ugh. I'm going back to buy and hold investing. Just bury my head in the sand and hope for the std 8% lt avg,
4/5/12
• !Report Abuse
John Rayhall: I don't like this move for them but if I owned it I would prob average down.
4/5/12
• !Report Abuse
Add a reply...

140 characters

Asif Suria
Spectrum Pharmaceuticals to Acquire Allos Therapeutics for $206 million $ALTH $SPPI http://bit.ly/HhE9Mt
4/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
AMAG CEO departs amid job cuts, failed merger $AMAG $ALTH
11/4/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

djw876
ALTH thoughts?
11/2/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
AMAG $AMAG shareholders Don't Approve Merger with Allos $ALTH; Will Pay $2M in Termination Fees
10/21/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Joe Springer
Sell Spectrum! http://seekingalpha.com/a/hmw5 $SPPI $OMPI $ALTH $BMY $BIIB $UHS $WCG $CYH $TARO $PDLI $EXEL #biotech #pharma #drugs #stocks
8/23/12
Reply (5)

• !Report Abuse
View all 5 replies
phemale60: not that sophisticated - just trade. I do alright tho for a newbie. I'll learn on my next vaca - sit and read. Then I'll know! ;-/
8/23/12
• !Report Abuse
Joe Springer: : )
8/23/12
• !Report Abuse
Add a reply...

140 characters

John Rayhall
Wow ALTH bought at $1.85! I remember when it was at $8 and analysts had a $15+ target on it. Not sure it's a good move for SPPI.
4/5/12
Reply (2)

• !Report Abuse
View all 2 replies
FortSumter: I have SPPI. Ugh. I'm going back to buy and hold investing. Just bury my head in the sand and hope for the std 8% lt avg,
4/5/12
• !Report Abuse
John Rayhall: I don't like this move for them but if I owned it I would prob average down.
4/5/12
• !Report Abuse
Add a reply...

140 characters

ALTH Allos Therapeutics, Inc.

ALTH

Allos Therapeutics, Inc.